Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

Oskar Hansson1, Åsa Petersén1, Marcel Leist1, Pierluigi Nicotera1, Roger F. Castilho1, Patrik Brundin1
1Section for Neuronal Survival, Wallenberg Neuroscience Center, Department of Physiological Sciences, Lund University, Sölvegatan 17, S-223 62 Lund, Sweden; and Faculty of Biology, Department of Molecular Toxicology, Konstanz University, D-78457 Konstanz, Germany

Tóm tắt

Huntington’s disease (HD) is a hereditary neurodegenerative disorder presenting with chorea, dementia, and extensive striatal neuronal death. The mechanism through which the widely expressed mutant HD gene mediates a slowly progressing striatal neurotoxicity is unknown. Glutamate receptor-mediated excitotoxicity has been hypothesized to contribute to the pathogenesis of HD. Here we show that transgenic HD mice expressing exon 1 of a human HD gene with an expanded number of CAG repeats (line R6/1) are strongly protected from acute striatal excitotoxic lesions. Intrastriatal infusions of the N -methyl- d -aspartate (NMDA) receptor agonist quinolinic acid caused massive striatal neuronal death in wild-type mice, but no damage in transgenic HD littermates. The remarkable neuroprotection in transgenic HD mice occurred at a stage when they had not developed any neurological symptoms caused by the mutant HD gene. At this stage there was no change in the number of striatal neurons and astrocytes in untreated R6/1 mice, although the striatal volume was decreased by 17%. Moreover, transgenic HD mice had normal striatal levels of NMDA receptors, calbindin D28k (calcium buffer), superoxide dismutase activity (antioxidant enzyme), Bcl-2 (anti-apoptotic protein), heat shock protein 70 (stress-induced anti-apoptotic protein), and citrate synthase activity (mitochondrial enzyme). We propose that the presence of exon 1 of the mutant HD gene induces profound changes in striatal neurons that render these cells resistant to excessive NMDA receptor activation.

Từ khóa


Tài liệu tham khảo

P S Harper Huntington’s Disease (Saunders, London, 1996).

10.1097/00005072-198511000-00003

10.1097/00005072-199501000-00013

10.1016/0092-8674(93)90585-E

10.1016/S0959-4388(96)80097-3

10.1038/378403a0

10.1038/378398a0

10.1038/nm0396-347

10.1073/pnas.93.10.5037

10.1038/ng0597-44

10.1016/S0092-8674(00)80514-0

10.1126/science.277.5334.1990

10.1038/ng1193-259

10.1073/pnas.92.19.8710

10.1016/0896-6273(95)90345-3

10.1038/ng0595-104

10.1038/263244a0

10.1038/263517a0

10.1016/0166-2236(90)90111-M

10.1212/WNL.42.4.733

10.1006/nbdi.1996.0002

10.1038/321168a0

10.1523/JNEUROSCI.11-06-01649.1991

10.1006/exnr.1993.1006

10.1126/science.6849138

10.1126/science.2841762

10.1016/S0092-8674(00)81369-0

10.1016/S0092-8674(00)80513-9

10.1046/j.1471-4159.1998.71062642.x

10.1016/S0006-8993(96)01387-X

10.1016/0076-6879(69)13006-2

10.1016/0003-2697(86)90026-6

10.1002/ar.1092310411

10.1126/science.3155875

10.1073/pnas.85.15.5733

10.2337/diabetes.48.3.649

10.1073/pnas.95.11.6480

10.1046/j.1471-4159.1997.69031039.x

10.1523/JNEUROSCI.11-12-03877.1991

10.1016/0306-4522(94)00494-P

10.1126/science.7901908

10.1016/S0006-8993(97)01469-8

10.1523/JNEUROSCI.15-05-03775.1995

10.1126/science.281.5381.1322

10.1093/emboj/17.21.6124

10.1523/JNEUROSCI.18-24-10277.1998

10.1016/0959-4388(92)90035-J

10.1016/0166-2236(94)90139-2

10.1073/pnas.89.14.6555

10.1212/WNL.48.2.306